论文部分内容阅读
目的:评价2007年南京市抗肿瘤药物利用情况。方法:采用金额和用药频度分析法。结果:用药总金额为2.53亿元,国产药占81.46%,其中江苏恒瑞制药占12.94%,植物来源的抗肿瘤药占40%。DDDs分析中居前的以内分泌激素类为主,不含任何植物来源的抗肿瘤药、铂剂及靶向治疗药物。结论:抗肿瘤药物利用以国产药物为主,西药金额与DDDs排序不一致,原因可能是临床倾向于选择新型抗肿瘤药物,但价格昂贵限制了使用,因此相应的国内仿制药获得了良好市场。
Objective: To evaluate the use of anti-tumor drugs in Nanjing in 2007. Methods: The amount and medication frequency analysis. Results: The total amount of medication was 253 million yuan, domestic medicine accounted for 81.46%, of which Jiangsu Hengrui pharmaceutical accounted for 12.94%, plant-derived anti-tumor drugs accounted for 40%. DDDs in front of the main endocrine hormones, does not contain any plant-derived anti-tumor drugs, platinum agents and targeted therapies. CONCLUSIONS: The use of anti-cancer drugs is dominated by domestic drugs. The discrepancies between the amount of western medicine and the DDDs rankings may be due to the clinical preference for new antitumor drugs. However, expensive anti-cancer drugs have limited their use and the corresponding domestic generic drugs have gained a good market.